Lysogene Presents Preliminary Results of LYS-SAF302 in P-II/III (AAVance) Trial for the Treatment of MPS IIIA in Children at ADVANCE 2022
Shots:
- The P-II/III (AAVance) trial evaluate LYS-SAF302 in 20 patients with MPS IIIA. The full study results are expected in mid-Sept. 2022, along with results from the (PROVide) PROs videos study
- The positive biomarker data was confirmed in additional subjects & at additional time points with a significant reduction of about 20% on avg. levels of total HS-derived oligosaccharides in the CSF relative to baseline levels at 6, 12, and 24mos., HS levels were reduced by 22% @24mos. with no significant effect on serum HS levels at 6, 12, or 24mos.
- Stable or continuously increasing cognitive, language & motor functions in 3 patients treated at ≤31mos. of age incl. patients with SGSH mutations associated with the severe disease phenotype
Ref: Bussinesswire | Image: Lysogene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
